 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...6263646566676869707172...7475» |
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: TWEYES: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (clinicaltrials.gov) - Dec 10, 2014
P4, N=3500, Recruiting, Sponsor: Novartis Pharmaceuticals
N=5000 --> 3500
- Lucentis (ranibizumab) / Roche, Novartis
Clinical: Ranibizumab in Patients With Branch Retinal Vein Occlusion (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=60, Recruiting, Sponsor: Dr. SamiUllah
- ||| razuprotafib subcutaneous (AKB-9778 SC) / Aadi Biosci, EyePoint Pharma
Enrollment closed, Monotherapy: The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Dec 10, 2014
P2, N=144, Active, not recruiting, Sponsor: Aerpio Therapeutics
N=5000 --> 3500 Recruiting --> Active, not recruiting
- ||| Beovu (brolucizumab-dbll) / Novartis
Enrollment closed: ESBA1008 Microvolume Study (clinicaltrials.gov) - Dec 10, 2014
P2, N=52, Active, not recruiting, Sponsor: Alcon Research
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab (clinicaltrials.gov) - Dec 7, 2014
P4, N=33, Completed, Sponsor: Vista Klinik
- PF582 (ranibizumab biosimilar) / Ligand
Enrollment closed: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) - Dec 7, 2014
P1/2, N=24, Active, not recruiting, Sponsor: Pfenex, Inc
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Dec 6, 2014
P4, N=54, Completed, Sponsor: University of Zurich
Recruiting --> Active, not recruiting N=75 --> 54 | Recruiting --> Completed
- | ASP8232 / Astellas
New P2 trial: A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Nov 28, 2014
P2, N=84, Not yet recruiting, Sponsor: Astellas Pharma Europe B.V.
- | Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: PROTECT: Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Nov 28, 2014
P1/2, N=88, Not yet recruiting, Sponsor: Leonard Feiner, MD, PhD
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients (clinicaltrials.gov) - Nov 20, 2014
P2/3, N=80, Not yet recruiting, Sponsor: East Florida Eye Institute
- Lucentis (ranibizumab) / Roche, Novartis
New P1 trial: Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide (clinicaltrials.gov) - Nov 19, 2014
P1, N=20, Not yet recruiting, Sponsor: Soll Eye
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=1, Completed, Sponsor: Southern New England Retina Associates
N=75 --> 54 | Recruiting --> Completed Recruiting --> Completed | N=10 --> 1
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: RESCUE: Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. (clinicaltrials.gov) - Nov 18, 2014
P1/2, N=8, Recruiting, Sponsor: Northern California Retina Vitreous Associates
Recruiting --> Completed | N=10 --> 1 Trial primary completion date: Sep 2014 --> Sep 2015
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=14, Completed, Sponsor: Stanford University
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Completed | N=20 --> 14
- |||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial completion: Safety and Efficacy Study of Ozurdex (clinicaltrials.gov) - Nov 18, 2014
P4, N=307, Completed, Sponsor: Allergan
Recruiting --> Completed | N=20 --> 14 Active, not recruiting --> Completed
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical: Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept (clinicaltrials.gov) - Nov 17, 2014
P=N/A, N=17, Not yet recruiting, Sponsor: Associated Retinal Consultants, Michigan
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Macugen (pegaptanib) / Bausch Health
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion (clinicaltrials.gov) - Nov 14, 2014
P=N/A, N=8, Terminated, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed N=40 --> 8 | Initiation date: Nov 2007 --> Mar 2008 | Recruiting --> Terminated | Trial primary completion date: Dec 2010 --> Jul 2010
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Phase classification, Combination therapy: Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma (clinicaltrials.gov) - Nov 10, 2014
P1, N=40, Active, not recruiting, Sponsor: Massachusetts Eye and Ear Infirmary
N=40 --> 8 | Initiation date: Nov 2007 --> Mar 2008 | Recruiting --> Terminated | Trial primary completion date: Dec 2010 --> Jul 2010 Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging (clinicaltrials.gov) - Nov 6, 2014
P1/2, N=8, Completed, Sponsor: Rush University Medical Center
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 N=10 --> 8
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial primary completion date: Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema (clinicaltrials.gov) - Nov 5, 2014
P2, N=20, Active, not recruiting, Sponsor: Retina Vitreous Associates of Florida
N=10 --> 8 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Sep 2016
- ||| LKA651 / Novartis, MorphoSys
New P1 trial: A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Nov 3, 2014
P1, N=72, Not yet recruiting, Sponsor: Alcon Research
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen (clinicaltrials.gov) - Oct 24, 2014
P4, N=40, Recruiting, Sponsor: Anders Kvanta
- |||| Stivarga (regorafenib) / Bayer
Enrollment open: DREAM: Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (clinicaltrials.gov) - Oct 24, 2014
P2a, N=540, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Sep 2016 Not yet recruiting --> Recruiting
- || PF 4634817 / Pfizer
Enrollment status: A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema (clinicaltrials.gov) - Oct 21, 2014
P2, N=200, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment status: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (clinicaltrials.gov) - Oct 21, 2014
P3, N=644, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Recruiting Recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial initiation date: 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Oct 20, 2014
P1/2, N=10, Completed, Sponsor: University of Illinois at Chicago
Recruiting --> Recruiting Active, not recruiting --> Completed | Initiation date: Jun 2010 --> Sep 2010
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial initiation date, Trial primary completion date: Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=100, Recruiting, Sponsor: Southern California Desert Retina Consultants, MC
Active, not recruiting --> Completed | Initiation date: Jun 2010 --> Sep 2010 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: Jun 2017 --> Sep 2017
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial initiation date: Treatment of Failing Blebs With Ranibizumab (clinicaltrials.gov) - Oct 17, 2014
P1, N=6, Completed, Sponsor: The New York Eye & Ear Infirmary
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: Jun 2017 --> Sep 2017 Recruiting --> Completed | Initiation date: Jun 2007 --> Jun 2000
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab and Bevacizumab for Diabetic Macular Edema (clinicaltrials.gov) - Oct 15, 2014
P2, N=56, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Recruiting --> Completed | Initiation date: Jun 2007 --> Jun 2000 N=15 --> 56
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial, Head-to-Head: SALUTE-D: Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME (clinicaltrials.gov) - Oct 15, 2014
P3, N=104, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: TIDE AMD: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Oct 11, 2014
P4, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Combination therapy: Revolution: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study (clinicaltrials.gov) - Oct 11, 2014
P2, N=12, Completed, Sponsor: Retina Associates of Florida, P.A.
N=15 --> 56 Active, not recruiting --> Completed | N=20 --> 12
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=300, Recruiting, Sponsor: NJ Retina
Active, not recruiting --> Completed | N=20 --> 12 Trial primary completion date: Oct 2014 --> Mar 2016
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (clinicaltrials.gov) - Oct 10, 2014
P4, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients (clinicaltrials.gov) - Oct 10, 2014
P3, N=380, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy (clinicaltrials.gov) - Oct 2, 2014
P1, N=10, Completed, Sponsor: The New York Eye Cancer Center
Trial primary completion date: Oct 2014 --> Mar 2016 Active, not recruiting --> Completed
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: SAFARI: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (clinicaltrials.gov) - Sep 30, 2014
P4, N=162, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema (clinicaltrials.gov) - Sep 30, 2014
P3, N=171, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Rayoqta (abicipar pegol) / Molecular Partners
Enrollment open: A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Sep 29, 2014
P2, N=25, Recruiting, Sponsor: Allergan
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Sep 29, 2014
P2, N=131, Completed, Sponsor: Lawrence S. Morse, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date: Safety and Efficacy of Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) - Sep 28, 2014
P1/2, N=30, Recruiting, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Jun 2016
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (clinicaltrials.gov) - Sep 22, 2014
P2, N=40, Recruiting, Sponsor: Greater Houston Retina Research
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
New P3 trial, Monotherapy: Stereotactic Radiotherapy for Wet AMD (STAR) (clinicaltrials.gov) - Sep 19, 2014
P3, N=411, Not yet recruiting, Sponsor: King's College Hospital NHS Trust
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: RETAIN: Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus (clinicaltrials.gov) - Sep 15, 2014
P3, N=373, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Ranibizumab and Bevacizumab for Diabetic Macular Edema (clinicaltrials.gov) - Sep 8, 2014
P2, N=15, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Aug 2015
- ||| razuprotafib subcutaneous (AKB-9778 SC) / Aadi Biosci, EyePoint Pharma
Enrollment change, Trial primary completion date, Monotherapy: The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Sep 5, 2014
P2, N=144, Recruiting, Sponsor: Aerpio Therapeutics
Trial primary completion date: Aug 2014 --> Aug 2015 N=120 --> 144 | Trial primary completion date: Dec 2014 --> Mar 2015
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change: Ranibizumab and Bevacizumab for Diabetic Macular Edema (clinicaltrials.gov) - Sep 4, 2014
P2, N=15, Active, not recruiting, Sponsor: National Eye Institute (NEI)
N=120 --> 144 | Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting | N=60 --> 15
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema (clinicaltrials.gov) - Aug 26, 2014
P1, N=6, Completed, Sponsor: University of Miami
Recruiting --> Active, not recruiting | N=60 --> 15 Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Jun 2010 --> Sep 2012
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: PEARL2t: Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) (clinicaltrials.gov) - Aug 22, 2014
P1/2, N=23, Completed, Sponsor: Hawaii Pacific Health
Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Jun 2010 --> Sep 2012 Active, not recruiting --> Completed | Trial primary completion date: Jul 2013 --> Aug 2014
- ||||| Stivarga (regorafenib) / Bayer
New P2a trial: DREAM: Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration (clinicaltrials.gov) - Aug 21, 2014
P2a, N=540, Not yet recruiting, Sponsor: Bayer